| Literature DB >> 12028031 |
Liang-Tsai Hsiao1, Hung-Ming Chung, Jen-Tsun Lin, Tzeon-Jye Chiou, Jin-Hwang Liu, Frank S Fan, Wei-Shu Wang, Chueh-Chuan Yen, Po-Min Chen.
Abstract
Between seven and 21% of patients treated with the specific tyrosine kinase inhibitor STI571 have been reported to develop mild-to-moderate severity of adverse cutaneous reactions. We report a patient in the blast crisis phase of chronic myeloid leukaemia who developed a life-threatening cutaneous reaction, Stevens-Johnson syndrome, following 1 week of STI571 therapy. This report may serve to remind the clinician about the possible severe cutaneous side-effects of STI571 before instituting more extensive clinical application of this agent in the future.Entities:
Mesh：
Substances：
Year: 2002 PMID： 12028031 DOI： 10.1046/j.1365-2141.2002.03499.x
Source DB: PubMed Journal: Br J Haematol ISSN： 0007-1048 Impact factor: 6.998